Cargando…

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis

PURPOSE: Intravenous (IV) zoledronic acid (ZA) is commonly used to delay skeletal complications secondary to bone metastases. However, the time associated with ZA administration may represent a significant burden to healthcare providers and patients. This study assessed the time associated with IV Z...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richhariya, Akshara, Qian, Yi, Zhao, Yufan, Chung, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304336/ https://www.ncbi.nlm.nih.gov/pubmed/22427731 http://dx.doi.org/10.2147/CMAR.S27693

Ejemplares similares

Effect of intravenous administration of zoledronic acid on jaw bone density in cases having skeletal metastasis: A prospective clinical study
por: Jain, Veena, et al.
Publicado: (2019)

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment
por: Brubaker, Kristen D, et al.
Publicado: (2006)

The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis
por: Hadji, P., et al.
Publicado: (2012)

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2019)

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
por: Akoury, Elie, et al.
Publicado: (2019)

Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs
por: Brewer, David John, et al.
Publicado: (2021)

Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivo
por: Landgraf, Marietta, et al.
Publicado: (2020)

Preventive Effects of Zoledronic Acid on Bone Metastasis in Mice Injected with Human Breast Cancer Cells
por: Jeong, Joon, et al.
Publicado: (2011)

Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
por: Haider, Marie-Therese, et al.
Publicado: (2014)

Histomorphometric Evaluation of Peri-Implant Bone Response to Intravenous Administration of Zoledronate (Zometa(®)) in an Osteoporotic Rat Model
por: Basudan, Amani M., et al.
Publicado: (2020)

Six monthly intravenous zoledronic acid in childhood osteoporosis
por: Munns, CF, et al.
Publicado: (2013)

The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
por: Hadji, Peyman, et al.
Publicado: (2012)

Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China
por: Wang, Qianyu, et al.
Publicado: (2020)

Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model
por: Hung, Tzong-Tyng, et al.
Publicado: (2011)

THU443 Acute Iridocyclitis Associated With Intravenous Zoledronic Acid
por: Ankireddypalli, Anvitha Reddy, et al.
Publicado: (2023)

A Case of Pseudogout Following Zoledronic Acid Administration
por: Hill, Alexander C, et al.
Publicado: (2021)

Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
por: Aft, Rebecca
Publicado: (2012)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
por: Generali, D, et al.
Publicado: (2008)

Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis
por: Gálvez, Rafael, et al.
Publicado: (2008)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

Halofuginone inhibits TGF-β/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis
por: Juárez, Patricia, et al.
Publicado: (2017)

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect
por: Lewiecki, E Michael
Publicado: (2010)

Acute Iridocyclitis Associated With Intravenous Zoledronic Acid: A Case Report
por: Ankireddypalli, Anvitha R, et al.
Publicado: (2023)

Cryoablation combined with zoledronic acid in comparison with cryoablation and zoledronic acid alone in the treatment of painful bone metastases
por: LI, FENQIANG, et al.
Publicado: (2014)

Zoledronic acid in the management of metastatic bone disease
por: Polascik, Thomas J, et al.
Publicado: (2008)

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy
por: Darvishi-Khezri, Hadi, et al.
Publicado: (2018)

Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption
por: Huang, Yanjuan, et al.
Publicado: (2020)

Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
por: Wang, Lianwei, et al.
Publicado: (2020)

Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis
por: Lorange, Justin-Pierre, et al.
Publicado: (2023)

Intravenous Zoledronate for a Patient with Paget's Disease
por: Kim, Ki-Choul
Publicado: (2014)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
por: Giveon, Sharon, et al.
Publicado: (2023)

Multicenter study of zoledronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017
por: Nakahara, Yoshiro, et al.
Publicado: (2019)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer
por: Jun, Jong Hwa
Publicado: (2017)

Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast, lung, or prostate cancer
por: Hagiwara, May, et al.
Publicado: (2013)

Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration
por: Nooh, Anas, et al.
Publicado: (2017)

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
por: Ubellacker, Jessalyn M., et al.
Publicado: (2017)

Assessment of the Effects of Zoledronic Acid Therapy on Bone Metabolic Indicators in Hormone-Resistant Prostate Cancer Patients with Bone Metastatasis
por: Demirtas, Abdullah, et al.
Publicado: (2011)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cl5rcot950m119a2m9imp43ohs